Article
As Congress moves toward possible approval of a new prescription drug program for Medicare recipients later this summer, how payments for cancer drugs and therapeutic services are determined may well hang in the balance.
How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond
The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice
Wealth Strategies for Today’s Physician: David Mandell, JD, MBA, Shares Insights from New Playbook
POLL: Is Your Practice Closed for the Holidays?
Maximizing the 2-Fold Benefits of Your Charitable Donations
Which Tax Treatment Is Best for Your Dermatology Practice?